In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using ⁶⁸Ga-NODAGA-c(NGR) Peptide

Figure 2

In vivo assessment of ⁶⁸Ga-NODAGA-c(NGR) uptake of control-untreated and actinonin- and bestatin-treated B16-F10 tumors. (a) Representative coronal decay-corrected PET images of control-untreated, bestatin-treated, and actinonin-treated B16-F10 tumor-bearing C57BL/6J mice 5 (upper row) and 10 days (lower row) after tumor cell inoculation and 90 min after intravenous injection of ⁶⁸Ga-NODAGA-c(NGR). Red arrows: B16-F10 tumor. (b) Quantitative decay-corrected SUV data analysis of ⁶⁸Ga-NODAGA-c(NGR) uptake of treated and untreated B16-F10 tumors 90 min after radiotracer injection. (c) Quantitative tumor-to-muscle ratio (T/M) analysis of treated and untreated B16-F10 tumors 90 min after intravenous injection of ⁶⁸Ga-NODAGA-c(NGR). SUVmean: standardized uptake value (mean). Significance level: . Data is presented as .

(a)

(b)

(c)